Compare Merck & Co., Inc. (MRK) vs Phillips 66 (PSX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Phillips 66 — how do they compare? Merck & Co., Inc. trades at $148.15 (market cap $366.28B), while Phillips 66 trades at $262 (market cap $103.40B). The key difference: Merck & Co., Inc. is far larger — about 3.5× Phillips 66's market cap, and Merck & Co., Inc. pays the higher dividend (2.29%). Which is the better fit depends on your goals.
| MRK | PSX | |
|---|---|---|
Market Cap | $366.28B | $103.40B |
Sector | Health | Energy |
52-Week High | $156.43 | $260.78 |
52-Week Low | $77.60 | $126.76 |
Enterprise Value | $413.04B | $119.87B |
Dividend Yield | 2.29% | 1.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MRK trades at $148.49, down 1.23% on the day, with a bullish technical signal from moving averages and support near $147. The company reported strong earnings beats in recent quarters, with Q3 2026 EPS expected at $2.22. Revenue reached $65.01B in 2025, and the acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline.
Outlook remains positive with a consensus price target of $157, offering ~6% upside. Risks include high P/E of 118.77 and competitive pressures in pharma. Institutional buying and a 67.57% buy rating from analysts support a constructive view, though net income margin of 4.77% warrants monitoring.
PSX trades at $259.14, up 1.59% today and near its 52-week high, supported by bullish technical signals and strong earnings beats in recent quarters. The stock shows robust profitability with a 24.02% ROE and attractive valuation metrics, including a P/E of 14.79. Recent news highlights momentum from high gas prices and refining efficiency gains, with a dividend of $1.27 payable in September 2026.
Outlook remains positive due to earnings momentum and sector tailwinds, but risks include volatile energy markets and declining revenue trends. Analysts are predominantly bullish with a $242.45 consensus target, though the current price exceeds this, suggesting near-term caution. Institutional buying and stable cash flow growth support long-term potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Phillips 66
Phillips 66 is an independent refiner with 12 refineries that have a total crude throughput capacity of 2.0 million barrels per day, or mmb/d, after converting its 255 mb/d Alliance refinery to a terminal. The midstream segment comprises extensive transportation and NGL processing assets. It also includes its DCP Midstream joint venture, which holds 45 natural gas processing facilities, 11 NGL fractionation plants, and a natural gas pipeline system with 58,000 miles of pipeline. Its CPChem chemical joint venture operates facilities in the United States and the Middle East and primarily produces olefins and polyolefins.
Read more on PSX →
